UNC569 is a novel, potent and selective small-molecule MER inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.

UNC2881 (UNC-2881) is a novel, potent and specific Mer tyrosine kinase inhibitor with potential utility for prevention and treatment of pathologic thrombosis.

NPS-1034 (NPS1034; NPS 1034) is a novel, potent dual inhibitor of the tyrosine kinases Met and Axl with potential antineoplastic activity.

XL-092 is a novel and potent inhibitor of the activity of Axl, Mer and C-Met kinase .

Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered.

Bemcentinib (formerly known as BGB324; R428) is a novel, potent and selective inhibitor of the RTK (receptor tyrosine kinase) Axl with potential anticancer activity.

SGI-7079 (SGI7079) is a novel, potent and selective Axl inhibitor with potential anti-inflammatory and anticancer activities.

Dubermatinib (formerly also known as TP-0903; TP-0903) is a novel, selective and orally bioavailable inhibitor of the AXL receptor tyrosine kinase with potential antineoplastic activity.

UNC2250 (UNC-2250) is a novel, potent and selective Mer inhibitor with potential antitumor activity.

LDC1267 (LDC-1267) is a novel, highly potent and selective TAM (Tyro3, Axl and Mer) kinase inhibitor with potential antitumor activity.